Charles Russell Speechlys advises Microba Life Sciences Limited on its acquisition of Invivo Clinical Limited
Charles Russell Speechlys advises Microba Life Sciences Limited on its acquisition of Invivo Clinical Limited
Charles Russell Speechlys has advised Microba Life Sciences Limited, an ASX listed (ASX: MAP) precision microbiome company driven to improve human health, on its acquisition of 100% of the issued share capital of Invivo Clinical Limited.
This deal marks the next phase of Microba’s international testing services growth strategy. By acquiring a market leading position, customer and geographical base in the United Kingdom, Microba will have deep access to the entire UK healthcare market, spanning private practice and the public NHS environment.
Microba Life Sciences Limited is a precision microbiome company driven to improve human health. Invivo Clinical Limited is a leading UK microbiome company which provides solutions to healthcare professionals and their patients.
Dr Luke Reid, Microba CEO, commented:
“Thank you to Jon, Jeff and the team for their invaluable support on this key strategic transaction for Microba – their advice was integral to its timely success.”
Jonathan Morley, Corporate Partner, commented:
“We were delighted to have been able to work with Microba on this pivotal transaction and are excited to see Invivo’s continued growth as part of the Microba group.”
The team was led by Corporate Partner Jonathan Morley with support from Associate Jeff Carvell.
